Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 50.7% in December

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 59,600 shares, a decrease of 50.7% from the November 30th total of 120,900 shares. Based on an average daily trading volume, of 149,700 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the shares of the company are short sold.

Bolt Biotherapeutics Trading Up 1.5 %

Shares of NASDAQ:BOLT traded up $0.01 during midday trading on Friday, hitting $0.52. 257,086 shares of the stock traded hands, compared to its average volume of 167,273. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $19.83 million, a PE ratio of -0.30 and a beta of 0.93. Bolt Biotherapeutics has a one year low of $0.48 and a one year high of $1.56. The business’s 50 day moving average is $0.59 and its two-hundred day moving average is $0.66.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). The business had revenue of $1.14 million during the quarter, compared to the consensus estimate of $1.02 million. Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. As a group, research analysts forecast that Bolt Biotherapeutics will post -1.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, November 13th. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $3.50.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Bolt Biotherapeutics stock. FMR LLC lifted its stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 33.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 115,386 shares of the company’s stock after buying an additional 28,773 shares during the quarter. FMR LLC owned about 0.30% of Bolt Biotherapeutics worth $75,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.